Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014001 · ClinicalTrials.gov registry record · Phase 4
CATIE- Schizophrenia Trial
A Phase 4 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 1,600
- Enrollment target
NCT00014001: Completed Phase 4 study, sponsored by National Institute of Mental Health (NIMH).
NCT00014001 is a Phase 4 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 1,600 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (209% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014001, a Phase 4 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,600 participants
- Enrollment target
Study Summary
The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG quetiapine
- DRUG ziprasidone
- DRUG perphenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2000-12 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
What the finished NCT00014001 record still lists
NCT00014001 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (209% higher).
The record links to 0 conditions, and to 5 interventions - of which risperidone is the first listed.
NCT00014001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014001 about?
NCT00014001 is a clinical study titled "CATIE- Schizophrenia Trial". The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people...
What is the current status of trial NCT00014001?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,600 participants. The study started on 2000-12. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00014001?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), quetiapine (DRUG), ziprasidone (DRUG), perphenazine (DRUG).
Who is sponsoring clinical trial NCT00014001?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00014001's enrollment target sits among peer trials
1,600 48th of 2000 higher than 1,952 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia